Mast Cell News Today : Breaking News, Live Updates & Top Stories | Vimarsana

us. >> we'll see you right back here next week. >> welcome to the program everyone. i'm christiane amanpour in normandy, france. this week we commemorate the 80th anniversary of the d-day landings, a turning point in history and a triumph of democracy over tyranny. i'm sitting at the american cemetery at colleville-sur-mer, which overlooks the normandy beaches which the allies invaded on june 6, 6, 1944. this lead to the liberation of western europe from nazi control. it's a reminder of the ultimate sacrifice that millions of people made to uphold democracy and to fight barbaric or a...

-- AYVAKIT data in patients with indolent systemic mastocytosis show durable efficacy and favorable safety supporting long-term treatment, consistent with...

The intricate relationship that exists between humans and the gut microbiome has become a hot research topic, and scientists are constantly uncovering new reasons why a healthy diet can lead to a healthier life.

Wall Street’s measure of how Cogent Biosciences Inc.’s KIT D816V inhibitor bezuclastinib (often shortened to bezu) might fare in mastocytosis against U.S. FDA cleared Ayvakit (avapritinib), the tyrosine kinase inhibitor from Blueprint Medicine Corp., caused the former’s stock (NASDAQ:COGT) to tumble, closing Dec. 11 at $4.06, down $4.58, or 53%.

The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called nonadvanced system mastocytosis, according to results of the Phase II SUMMIT trial reported by researchers at The University of Texas MD Anderson Cancer Center.